Renal safety of Long-Term Non-steroidal Anti-inflammatory drugs use in patients with ankylosing spondylitis

Abstract Objectives We investigate the renal safety of long-term non-steroidal anti-inflammatory drugs (NSAIDs) exposure in patients with ankylosing spondylitis (AS). Methods We analyzed electronic medical records from Asan Medical Center (AMC) and Seoul National University Bundang Hospital (SNUBH),...

Full description

Saved in:
Bibliographic Details
Main Authors: Young-Eun Kim, Seo Young Park, Ji Sung Lee, You-Jung Ha, Sooyoung Yoo, Seok Kim, Soo Min Ahn, Seokchan Hong, Chang‑Keun Lee, Bin Yoo, Ji Seon Oh, Yong‑Gil Kim
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-07146-8
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849238445215449088
author Young-Eun Kim
Seo Young Park
Ji Sung Lee
You-Jung Ha
Sooyoung Yoo
Seok Kim
Soo Min Ahn
Seokchan Hong
Chang‑Keun Lee
Bin Yoo
Ji Seon Oh
Yong‑Gil Kim
author_facet Young-Eun Kim
Seo Young Park
Ji Sung Lee
You-Jung Ha
Sooyoung Yoo
Seok Kim
Soo Min Ahn
Seokchan Hong
Chang‑Keun Lee
Bin Yoo
Ji Seon Oh
Yong‑Gil Kim
author_sort Young-Eun Kim
collection DOAJ
description Abstract Objectives We investigate the renal safety of long-term non-steroidal anti-inflammatory drugs (NSAIDs) exposure in patients with ankylosing spondylitis (AS). Methods We analyzed electronic medical records from Asan Medical Center (AMC) and Seoul National University Bundang Hospital (SNUBH), including 1,618 and 995 AS patients, respectively, with over one year of follow-up and no pre-existing kidney disease (baseline eGFR ≥ 60). NSAID exposure was quantified using the medication possession rate (MPR), and its impact on estimated glomerular filtration rate (eGFR) changes was assessed using linear mixed-effects models. Two approaches were employed: a 1-year interval analysis assuming a stable effect over time without time interaction, and a 3-year interval analysis incorporating time interaction to evaluate cumulative NSAID effects and changes in the relationship with eGFR decline over time. Results In the analysis without time interaction, NSAID use was associated with a decline in annual eGFR, with patients having 100% NSAID use experiencing a decrease in eGFR (β, -0.7; 95% CI: -1.1 to -0.3) compared to those with no NSAID use. A meta-analysis showed that every 1% increase in NSAID MPR associate with eGFR decline (β, -0.007; 95% CI: -0.011 to -0.004). However, the time-interaction analysis found no significant cumulative eGFR decline across most time points, except at the 9-year follow-up in SNUBH (β, -5.1; 95% CI, -9.2 to -1.1) and 18-year follow-up in AMC (β, -8.9; 95% CI, -15.9 to -1.9). Conclusion This study demonstrates that while NSAID use may affect renal function in the short term, its long-term cumulative effects on renal impairment appear non-significant.
format Article
id doaj-art-236b855b11f24c73b22b5e192e2d831e
institution Kabale University
issn 2045-2322
language English
publishDate 2025-07-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-236b855b11f24c73b22b5e192e2d831e2025-08-20T04:01:36ZengNature PortfolioScientific Reports2045-23222025-07-0115111110.1038/s41598-025-07146-8Renal safety of Long-Term Non-steroidal Anti-inflammatory drugs use in patients with ankylosing spondylitisYoung-Eun Kim0Seo Young Park1Ji Sung Lee2You-Jung Ha3Sooyoung Yoo4Seok Kim5Soo Min Ahn6Seokchan Hong7Chang‑Keun Lee8Bin Yoo9Ji Seon Oh10Yong‑Gil Kim11Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of MedicineDepartment of Statistics and Data Science, Korea National Open UniversityClinical Research Center, Asan Institute for Life Sciences, Asan Medical CenterDivision of Rheumatology, Department of Internal Medicine, Seoul National University Bundang HospitalHealthcare ICT Research Center, Office of eHealth Research and Businesses, Seoul National University Bundang HospitalHealthcare ICT Research Center, Office of eHealth Research and Businesses, Seoul National University Bundang HospitalDivision of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of MedicineDivision of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of MedicineDivision of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of MedicineDivision of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of MedicineDivision of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of MedicineDivision of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of MedicineAbstract Objectives We investigate the renal safety of long-term non-steroidal anti-inflammatory drugs (NSAIDs) exposure in patients with ankylosing spondylitis (AS). Methods We analyzed electronic medical records from Asan Medical Center (AMC) and Seoul National University Bundang Hospital (SNUBH), including 1,618 and 995 AS patients, respectively, with over one year of follow-up and no pre-existing kidney disease (baseline eGFR ≥ 60). NSAID exposure was quantified using the medication possession rate (MPR), and its impact on estimated glomerular filtration rate (eGFR) changes was assessed using linear mixed-effects models. Two approaches were employed: a 1-year interval analysis assuming a stable effect over time without time interaction, and a 3-year interval analysis incorporating time interaction to evaluate cumulative NSAID effects and changes in the relationship with eGFR decline over time. Results In the analysis without time interaction, NSAID use was associated with a decline in annual eGFR, with patients having 100% NSAID use experiencing a decrease in eGFR (β, -0.7; 95% CI: -1.1 to -0.3) compared to those with no NSAID use. A meta-analysis showed that every 1% increase in NSAID MPR associate with eGFR decline (β, -0.007; 95% CI: -0.011 to -0.004). However, the time-interaction analysis found no significant cumulative eGFR decline across most time points, except at the 9-year follow-up in SNUBH (β, -5.1; 95% CI, -9.2 to -1.1) and 18-year follow-up in AMC (β, -8.9; 95% CI, -15.9 to -1.9). Conclusion This study demonstrates that while NSAID use may affect renal function in the short term, its long-term cumulative effects on renal impairment appear non-significant.https://doi.org/10.1038/s41598-025-07146-8Ankylosing spondylitisNon-steroidal anti-inflammatory drugsKidneySafety
spellingShingle Young-Eun Kim
Seo Young Park
Ji Sung Lee
You-Jung Ha
Sooyoung Yoo
Seok Kim
Soo Min Ahn
Seokchan Hong
Chang‑Keun Lee
Bin Yoo
Ji Seon Oh
Yong‑Gil Kim
Renal safety of Long-Term Non-steroidal Anti-inflammatory drugs use in patients with ankylosing spondylitis
Scientific Reports
Ankylosing spondylitis
Non-steroidal anti-inflammatory drugs
Kidney
Safety
title Renal safety of Long-Term Non-steroidal Anti-inflammatory drugs use in patients with ankylosing spondylitis
title_full Renal safety of Long-Term Non-steroidal Anti-inflammatory drugs use in patients with ankylosing spondylitis
title_fullStr Renal safety of Long-Term Non-steroidal Anti-inflammatory drugs use in patients with ankylosing spondylitis
title_full_unstemmed Renal safety of Long-Term Non-steroidal Anti-inflammatory drugs use in patients with ankylosing spondylitis
title_short Renal safety of Long-Term Non-steroidal Anti-inflammatory drugs use in patients with ankylosing spondylitis
title_sort renal safety of long term non steroidal anti inflammatory drugs use in patients with ankylosing spondylitis
topic Ankylosing spondylitis
Non-steroidal anti-inflammatory drugs
Kidney
Safety
url https://doi.org/10.1038/s41598-025-07146-8
work_keys_str_mv AT youngeunkim renalsafetyoflongtermnonsteroidalantiinflammatorydrugsuseinpatientswithankylosingspondylitis
AT seoyoungpark renalsafetyoflongtermnonsteroidalantiinflammatorydrugsuseinpatientswithankylosingspondylitis
AT jisunglee renalsafetyoflongtermnonsteroidalantiinflammatorydrugsuseinpatientswithankylosingspondylitis
AT youjungha renalsafetyoflongtermnonsteroidalantiinflammatorydrugsuseinpatientswithankylosingspondylitis
AT sooyoungyoo renalsafetyoflongtermnonsteroidalantiinflammatorydrugsuseinpatientswithankylosingspondylitis
AT seokkim renalsafetyoflongtermnonsteroidalantiinflammatorydrugsuseinpatientswithankylosingspondylitis
AT soominahn renalsafetyoflongtermnonsteroidalantiinflammatorydrugsuseinpatientswithankylosingspondylitis
AT seokchanhong renalsafetyoflongtermnonsteroidalantiinflammatorydrugsuseinpatientswithankylosingspondylitis
AT changkeunlee renalsafetyoflongtermnonsteroidalantiinflammatorydrugsuseinpatientswithankylosingspondylitis
AT binyoo renalsafetyoflongtermnonsteroidalantiinflammatorydrugsuseinpatientswithankylosingspondylitis
AT jiseonoh renalsafetyoflongtermnonsteroidalantiinflammatorydrugsuseinpatientswithankylosingspondylitis
AT yonggilkim renalsafetyoflongtermnonsteroidalantiinflammatorydrugsuseinpatientswithankylosingspondylitis